Battle coming for blockbuster cholesterol drugs By: CNBC.com News July 24, 2015 at 15:59 PM EDT One large pharmacy benefit manager warns that costs from new PCSK9 drugs could reach as high as $150 billion annually, straining insurance plans. Read More >> Related Stocks: Amgen CVS Health Corp Gilead Sciences Regeneron Pharmaceuticals Sanofi-Aventis S.A. ADR